Trial Profile
To evaluate the efficacy and safety of Apatinib in patients with metastatic colorectal cancer refractory to standard therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jun 2017 New trial record
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.